(BAK) Braskem - Ratings and Ratios
Exchange: NYSE • Country: Brazil • Currency: USD • Type: Common Stock • ISIN: US1055321053
BAK EPS (Earnings per Share)
BAK Revenue
BAK: Chemicals, Petrochemicals, Plastics, Fuels, Solvents, PVC, Caustic Soda
Braskem SA Class A (NYSE:BAK) is a leading manufacturer and supplier of petrochemicals and fuels, operating globally with a significant presence in Brazil and international operations across multiple countries. The companys diversified product portfolio includes polyethylene, polypropylene, and other thermoplastic resins, as well as basic petrochemicals and fuels. Braskems extensive operations and product range position it as a key player in the commodity chemicals sector.
The companys global footprint is substantial, with operations in the Americas, Europe, and Asia, allowing it to serve a broad customer base. Braskems product applications span various industries, including packaging, automotive, construction, and consumer goods, making it a critical component in the global supply chain. As a subsidiary of NSP Investimentos S.A. - Em Recuperacao Judicial, Braskems financial and operational performance is closely tied to its parent companys situation.
Analyzing the technical data, Braskems stock (BAK) is currently trading at $3.62, below its 20-day Simple Moving Average (SMA) of $3.75, indicating a potential short-term downtrend. However, the stock is above its 52-week low of $2.91, suggesting some resilience. The Average True Range (ATR) of 0.20 (or 5.39%) indicates moderate volatility. Given the current SMA20 and SMA50 levels, a potential support zone is forming around $3.60-$3.70.
From a fundamental perspective, Braskems market capitalization stands at $1.501 billion USD, with a forward Price-to-Earnings (P/E) ratio of 9.78, suggesting that the stock may be undervalued relative to its future earnings potential. The Return on Equity (RoE) of 414.20% is exceptionally high, indicating strong profitability. However, the absence of a trailing P/E ratio complicates the analysis, suggesting either a recent loss or an unusually high earnings fluctuation.
Forecasting Braskems stock performance involves integrating both technical and fundamental insights. Given the current technical indicators and fundamental data, a potential short-term target for BAK could be around $4.00, representing a 10% increase from the current price. This is based on the stocks historical volatility and its proximity to the SMA20. However, achieving this target would require a stabilization or improvement in the global commodity chemicals market, as well as positive developments regarding its parent companys judicial recovery status. Long-term prospects would depend on Braskems ability to maintain its operational efficiency, manage raw material costs, and navigate the global economic landscape.
Additional Sources for BAK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
BAK Stock Overview
Market Cap in USD | 1,502m |
Sector | Basic Materials |
Industry | Chemicals |
GiC Sub-Industry | Commodity Chemicals |
IPO / Inception | 1999-01-13 |
BAK Stock Ratings
Growth Rating | -63.1 |
Fundamental | -41.0 |
Dividend Rating | 1.0 |
Rel. Strength | -47.9 |
Analysts | 3.5 of 5 |
Fair Price Momentum | 2.72 USD |
Fair Price DCF | - |
BAK Dividends
Currently no dividends paidBAK Growth Ratios
Growth Correlation 3m | 8% |
Growth Correlation 12m | -88.4% |
Growth Correlation 5y | -56.8% |
CAGR 5y | -14.17% |
CAGR/Max DD 5y | -0.16 |
Sharpe Ratio 12m | -1.39 |
Alpha | -58.70 |
Beta | 0.904 |
Volatility | 55.68% |
Current Volume | 792.4k |
Average Volume 20d | 870.6k |
As of June 24, 2025, the stock is trading at USD 3.46 with a total of 792,406 shares traded.
Over the past week, the price has changed by -9.42%, over one month by -10.59%, over three months by -4.68% and over the past year by -48.51%.
Probably not. Based on ValueRay´s Fundamental Analyses, Braskem (NYSE:BAK) is currently (June 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -41.04 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BAK is around 2.72 USD . This means that BAK is currently overvalued and has a potential downside of -21.39%.
Braskem has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold BAK.
- Strong Buy: 2
- Buy: 0
- Hold: 6
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, BAK Braskem will be worth about 2.9 in June 2026. The stock is currently trading at 3.46. This means that the stock has a potential downside of -15.03%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 4.8 | 39% |
Analysts Target Price | 4.8 | 39% |
ValueRay Target Price | 2.9 | -15% |